BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23666235)

  • 1. Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
    Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mastrangelo S; Migliorati R; Bertolini P; Colosimo C; Riccardi R
    J Neurooncol; 2013 Jul; 113(3):513-8. PubMed ID: 23666235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma.
    Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Mastrangelo S; Maurizi P; Migliorati R; Bertolini P; Pastore M; Colosimo C; Riccardi R
    Eur J Cancer; 2010 Nov; 46(16):2943-9. PubMed ID: 20538454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
    Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
    Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
    Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
    Neuro Oncol; 2009 Oct; 11(5):556-61. PubMed ID: 19289491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
    Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
    Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
    Terasaki M; Bouffet E; Katsuki H; Fukushima S; Shigemori M
    Surg Neurol; 2008 Jan; 69(1):46-50. PubMed ID: 18054615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
    Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
    Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
    Lee EQ; Puduvalli VK; Reid JM; Kuhn JG; Lamborn KR; Cloughesy TF; Chang SM; Drappatz J; Yung WK; Gilbert MR; Robins HI; Lieberman FS; Lassman AB; McGovern RM; Xu J; Desideri S; Ye X; Ames MM; Espinoza-Delgado I; Prados MD; Wen PY
    Clin Cancer Res; 2012 Nov; 18(21):6032-9. PubMed ID: 22923449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
    Newlands ES; Foster T; Zaknoen S
    Br J Cancer; 2003 Jul; 89(2):248-51. PubMed ID: 12865911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
    Korones DN; Smith A; Foreman N; Bouffet E
    Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
    Ridola V; Barone G; Lazzareschi I; Ruggiero A; Rizzo D; Riccardi R
    J Neurooncol; 2011 May; 103(1):147-53. PubMed ID: 20811928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
    Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
    Rubie H; Geoerger B; Frappaz D; Schmitt A; Leblond P; Ndiaye A; Aerts I; Le Deley MC; Gentet JC; Paci A; Chastagner P; Dias N; Djafari L; Pasquet M; Chatelut E; Landman-Parker J; Corradini N; Vassal G
    Eur J Cancer; 2010 Oct; 46(15):2763-70. PubMed ID: 20558056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
    Holdhoff M; Ye X; Supko JG; Nabors LB; Desai AS; Walbert T; Lesser GJ; Read WL; Lieberman FS; Lodge MA; Leal J; Fisher JD; Desideri S; Grossman SA; Wahl RL; Schiff D
    Neuro Oncol; 2017 Jun; 19(6):845-852. PubMed ID: 28371832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
    Blakeley JO; Grossman SA; Mikkelsen T; Rosenfeld MR; Peereboom D; Nabors LB; Chi AS; Emmons G; Garcia Ribas I; Supko JG; Desideri S; Ye X
    J Neurooncol; 2015 Oct; 125(1):123-31. PubMed ID: 26285766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
    Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
    Karavasilis V; Kotoula V; Pentheroudakis G; Televantou D; Lambaki S; Chrisafi S; Bobos M; Fountzilas G
    J Neurol; 2013 Jun; 260(6):1469-80. PubMed ID: 23292205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.